Carbidopa for the Treatment of Cancer
AssigneeTexas Tech University System
InventorsVadivel Ganapathy, Yangzom D. Bhutia, Babu Ellappan, Sabarish Ramachandran
Life of this patent
Estimating the term…
Abstract
The present invention includes a method of inhibiting or reducing mTOR signaling or inhibition of indoleamine dioxygenase-1 (IDO1) in a subject with a proliferative disease, which comprises administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof.
Claims37
A method of inhibiting or reducing mTOR signaling or inhibition of indoleamine dioxygenase-1 (IDO1) in a subject with a proliferative disease which comprises administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof.
A method for treating a subject with a proliferative disease comprising:
- administering to the subject in need of such treatment a therapeutically effective amount of Carbidopa or a salt thereof, wherein the cell proliferative disorder is characterized by the need to inhibit or reduce mTOR signaling or inhibit IDO1, wherein the proliferative disease is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome (HES), bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, or hematologic malignancy.
A method for treating a subject with breast or pancreatic cancer comprising:
- obtaining a sample from the subject suspected of having breast or pancreatic cancer;
- determining from the subject sample that the subject has a need of inhibiting or reducing mTOR signaling or inhibition of indoleamine dioxygenase-1 (IDO1);
- and
- administering to the subject in need of such treatment a therapeutically effective amount of Carbidopa or a salt thereof, wherein the breast or pancreatic cancer is characterized by the need to inhibit or reduce mTOR signaling or inhibit IDO1.
A method for specifically inhibiting or reducing mTOR signaling or inhibition of indoleamine dioxygenase-1 (IDO1) comprising:
- determining if a subject has a proliferative disease;
- obtaining a subject sample to determine a need to inhibit or reduce mTOR signaling or inhibit IDO1;
- and
- administering to a mammal in need of such treatment a therapeutically effective amount of Carbidopa or a salt thereof sufficient inhibit or reduce mTOR signaling or inhibit IDO1 in the mammal.
A method of determining the effectiveness of Carbidopa or an active derivative thereof, the method comprising:
- (a) measuring the serum or plasma based levels of mTOR signaling or of indoleamine dioxygenase-1 (IDO1);
- (b) administering the candidate drug to a first subset of the patients, and a placebo to a second subset of the patients;
- (c) determining the activity of mTOR signaling or indoleamine dioxygenase-1 (IDO1) in the first and second subset of patients;
- (d) determining if the Carbidopa or the active derivative thereof reduce or inhibit mTOR signaling or indoleamine dioxygenase-1 activity;
- (e) repeating step (a) after the administration of the candidate drug or the placebo;
- and
- (f) determining if the candidate drug modifies the activity of mTOR signaling or IDO1 over the course of the treatment.
Dependencies are inferred from the claim text.